Drug residues store in the body following cessation of use: Impacts on neuroendocrine balance and behavior - Use of the Hubbard sauna regimen to remove toxins and restore health

Medical Hypotheses

Volumn 68, Issue 4, 2007, Pages 868-879

  Cecchini, Marie ^a   LoPresti, Vincent ^a  

^a Foundation for Advancements in Science and Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPRAZOLAM; BENZODIAZEPINE; CANNABIS; COCAINE; DIAZEPAM; FLUOXETINE; HORMONE; ILLICIT DRUG; LEPTIN; LYSERGIDE; METHAMPHETAMINE; PHENCYCLIDINE; RESISTIN; STREET DRUG; TUMOR NECROSIS FACTOR ALPHA; XENOBIOTIC AGENT;

ADIPOSE TISSUE; ARTICLE; BEHAVIOR; BRAIN TISSUE; CELL MEMBRANE; CHRONIC FATIGUE SYNDROME; COGNITION; DATA ANALYSIS; DETOXIFICATION; DEVELOPED COUNTRY; DRUG ABUSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG EXPOSURE; DRUG RETENTION; DRUG STORAGE; DRUG WITHDRAWAL; ENERGY; ENVIRONMENTAL FACTOR; EXERCISE; FORENSIC MEDICINE; GENETICS; HALF LIFE TIME; HORMONE ACTION; HORMONE BLOOD LEVEL; HUBBARD SAUNA REGIMEN; HUMAN; INFLAMMATION; LEGAL ASPECT; LIPOPHILICITY; MEDICAL PRACTICE; MEDICAL RESEARCH; NEUROENDOCRINE SYSTEM; NUTRITIONAL DEFICIENCY; OBSERVATION; PERCEPTION; POLLUTANT; PRIORITY JOURNAL; RISK FACTOR; SAUNA; SOLUBILITY; SYMPTOM; TARGET ORGAN; TISSUE LEVEL; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; DRUG RESIDUES; FOOD; HUMAN BODY; HUMANS; INFLAMMATION; LEPTIN; MODELS, BIOLOGICAL; NEUROSECRETORY SYSTEMS; PHARMACEUTICAL PREPARATIONS; STEAM BATH; STREET DRUGS; TOXINS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846376065     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.08.035     Document Type: Article

References (92)

1. Environmental Working Group. Body Burden - The Pollution in People; 2003. (accessed 00.08.06).
2. Crinnion W.J. Environmental medicine, part one: the human burden of environmental toxins and their common health effects. Altern Med Rev 5 (2000) 52-63
3. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data (NHANES). Third National Report on Human Exposure to Environmental Chemicals. Hyattsville, MD, US, Department of Health and Human Services; 2006.
4. Colborn T. Pesticides - how research has succeeded and failed to translate science into policy: endocrinological effects on wildlife. Environ Health Perspect 103 Suppl. 6 (1995) 81-85
5. Miller C.S. Are we on the threshold of a new theory of disease? Toxicant-induced loss of tolerance and its relationship to addiction and abdiction. Toxicol Ind Health 15 (1999) 284-294
6. Lieber C.S. Microsomal ethanol-oxidizing system. Enzyme 37 (1987) 45-56
7. Center for Disease Control and Prevention (CDC). NHANES III Priority Toxicant Reference Range Study Data File Series 11, No. 4A. Third National Health and Nutrition Examination Survey (NHANES III 1988-94); 2000.
8. Colborn T. Environmental estrogens: health implications for humans and wildlife. Environ Health Perspect 103 Suppl. 7 (1995) 135-136
9. Willes R.F., Nestmann E.R., Miller P.A., Orr J.C., and Munro I.C. Scientific principles for evaluating the potential for adverse effects from chlorinated organic chemicals in the environment. Regul Toxicol Pharmacol 18 (1993) 313-356
10. Yokogawa K., Ishizaki J., Ohkuma S., and Miyamoto K. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Meth Find Exp Clin Pharmacol 24 (2002) 81-93
11. Altman J. A biological view of drug abuse. Mol Med Today 2 (1996) 237-241
12. Buchert R., Obrocki J., Thomasius R., et al. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl Med Commun 22 (2001) 889-897
13. Morgan C.J., Riccelli M., Maitland C.H., and Curran H.V. Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend 75 (2004) 301-308
14. Stoman A. The absorption, distribution, and excretion of drugs and poisons and their metabolites. Progress in Chemical Toxicology (1974), Academic Press, London p. 1-99
15. Chiang C.N., and Hawks R.L. Implications of drug levels in body fluids: basic concepts. NIDA Res Monogr 73 (1986) 62-83
16. Levisky J.A., Bowerman D.L., Jenkins W.W., and Karch S.B. Drug deposition in adipose tissue and skin: evidence for an alternative source of positive sweat patch tests. Forensic Sci Int 110 (2000) 35-46
17. Axelrod J., Brady R.O., Witkop B., and Evarts E.V. The distribution and metabolism of lysergic acid diethylamide. Ann NY Acad Sci 66 (1957) 435-444
18. Nayak P.K., Misra A.L., and Mule S.J. Physiological disposition and biotransformation of (3H) cocaine in acutely and chronically treated rats. J Pharmacol Exp Ther 196 (1976) 556-569
19. Weiss R.D., and Gawin F.H. Protracted elimination of cocaine metabolites in long-term high-dose cocaine abusers. Am J Med 85 (1988) 879-880
20. Cone E.J., and Weddington Jr. W.W. Prolonged occurrence of cocaine in human saliva and urine after chronic use. J Anal Toxicol 13 (1989) 65-68
21. Levisky J.A., Bowerman D.L., Jenkins W.W., Johnson D.G., and Karch S.B. Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci Int 121 (2001) 157-160
22. Misra A.L., Pontani R.B., and Bartolomeo J. Persistence of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioural effects. Res Commun Chem Pathol Pharmacol 24 (1979) 431-445
23. Sparber S.B., Nagasawa S., and Burklund K.E. A mobilizable pool of d-amphetamine in adipose after daily administration to rats. Res Commun Chem Pathol Pharmacol 18 (1977) 423-431
24. Coveney J.R., and Sparber S.B. Delayed effects of amphetamine or phencyclidine: interaction of food deprivation, stress and dose. Pharmacol Biochem Behav 36 (1990) 443-449
25. Refaai M.A., Nguyen P.N., Steffensen T.S., Evans R.J., Cluette-Brown J.E., and Laposata M. Liver and adipose tissue fatty acid ethyl esters obtained at autopsy are postmortem markers for premortem ethanol intake. Clin Chem 48 (2002) 77-83
26. Refaai M.A., Nguyen P.N., Cluette-Brown J.E., and Laposata M. Ethyl arachidonate is the predominant fatty acid ethyl ester in the brains of alcohol-intoxicated subjects at autopsy. Lipids 38 (2003) 269-273
27. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24 3 (1993) 203-220
28. Daniel W.A., and Wojcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol 80 (1997) 62-68
29. Igari Y., Sugiyama Y., Sawada Y., Iga T., and Hanano M. Tissue distribution of 14C-diazepam and its metabolites in rats. Drug Metab Dispos 10 (1982) 676-679
30. Martin B.R., Bailey B.B., Awaya H., May E.L., and Narasimhachari N. In vitro metabolism of 1-phenyl-1-cyclohexene, a pyrolysis product of phencyclidine. Drug Metab Dispos 10 (1982) 685-689
31. Minder S., Daniel W.A., Clausen J., and Bickel M.H. Adipose tissue storage of drugs as a function of binding competition. In vitro studies with distribution dialysis. J Pharm Pharmacol 46 (1994) 313-315
32. Blouin R.A., Kolpek J.H., and Mann H.J. Influence of obesity on drug disposition. Clin Pharm 6 (1987) 706-714
33. Blouin R.A., and Warren G.W. Pharmacokinetic considerations in obesity. J Pharm Sci 88 (1999) 1-7
34. Abernethy D.R., Greenblatt D.J., Divoll M., and Shader R.I. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci 71 (1982) 942-944
35. Abernethy D.R., Greenblatt D.J., Divoll M., and Shader R.I. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol 23 (1983) 369-376
36. Caraco Y., Zylber-Katz E., Berry E.M., and Levy M. Significant weight reduction in obese subjects enhances carbamazepine elimination. Clin Pharmacol Ther 51 (1992) 501-506
37. Caraco Y., Zylber-Katz E., Berry E.M., and Levy M. Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother 29 (1995) 843-847
38. Leighty E.G., Fentiman Jr. A.F., and Foltz R.L. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 14 (1976) 13-28
39. Lemberger L., Silberstein S.D., Axelrod J., and Kopin I.J. Marihuana: studies on the disposition and metabolism of δ-9-tetrahydrocannabinol in man. Science 170 (1970) 1320-1322
40. Mason A.P., and McBay A.J. Cannabis: pharmacology and interpretation of effects. J Forensic Sci 30 (1985) 615-631
41. Nahas G.G. The pharmacokinetics of THC in fat and brain: resulting functional responses to marihuana smoking. Hum Psychopharmacol 16 (2001) 247-255
42. DeLaurentis M.J., McNeil K., Mann A.J., Clark S., and Greenwood H.M. An EMIT assay for cannabinoid metabolites in urine. NIDA Res Monogr 42 (1982) 69-84
43. Johansson E., Noren K., Sjovall J., and Halldin M.M. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3 (1989) 35-38
44. Harvey D.J., Leuschner J.T., and Paton W.D. Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of delta 1-tetrahydrocannabinol in the rabbit. J Chromatogr 239 (1982) 243-250
45. Dackis C.A., Pottash A.L., Annitto W., and Gold M.S. Persistence of urinary marijuana levels after supervised abstinence. Am J Psychiatry 139 (1982) 1196-1198
46. Niveau G. Cannabis-related flash-back, a medico-legal case. Encephale 28 (2002) 77-79
47. Nahas G.G., Frick H.C., Lattimer J.K., Latour C., and Harvey D. Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa. Hum Psychopharmacol 17 (2002) 103-113
48. Fride E. The endocannabinoid-CB(1) receptor system in pre- and postnatal life. Eur J Pharmacol 500 (2004) 289-297
49. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
50. Matochik J.A., London E.D., Yildiz B.O., et al. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J Clin Endocrinol Metab 90 (2005) 2851-2854
51. Ahima R.S. Central actions of adipocyte hormones. Trends Endocrinol Metab 16 (2005) 307-313
52. Havel P.J. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13 (2002) 51-59
53. Vettor R., Milan G., Rossato M., and Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 22 Suppl. 2 (2005) 3-10
54. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002;60:S1-14; discussion 2002:S68-84, 85-7.
55. Di Marzo V., Goparaju S.K., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
56. Harrold J.A., and Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating?. Br J Nutr 90 (2003) 729-734
57. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev Nov 23 (2005)
58. Shalev U., Yap J., and Shaham Y. Leptin attenuates acute food deprivation-induced relapse to heroin seeking. J Neurosci 21 (2001) RC129
59. Kiefer F., and Wiedemann K. Neuroendocrine pathways of addictive behaviour. Addict Biol 9 (2004) 205-212
60. Kiefer F., Jahn H., Jaschinski M., et al. Leptin: a modulator of alcohol craving?. Biol Psychiatry 49 (2001) 782-787
61. Kristensen P., Judge M.E., Thim L., et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393 (1998) 72-76
62. Tsuruta Y., Yoshimatsu H., Hidaka S., Kondou S., Okamoto K., and Sakata T. Hyperleptinemia in A(y)/a mice upregulates arcuate cocaine- and amphetamine-regulated transcript expression. Am J Physiol Endocrinol Metab 282 (2002) E967-E973
63. Murphy K.G. Dissecting the role of cocaine- and amphetamine-regulated transcript (CART) in the control of appetite. Brief Funct Genomic Proteomic 4 (2005) 95-111
64. Kask A., Schioth H.B., Mutulis F., Wikberg J.E., and Rago L. Anorexigenic cocaine- and amphetamine-regulated transcript peptide intensifies fear reactions in rats. Brain Res 857 (2000) 283-285
65. Crowley W.R., Ramoz G., Keefe K.A., Torto R., Kalra S.P., and Hanson G.R. Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats. Neuroscience 132 (2005) 167-173
66. Takaya K., Ogawa Y., Isse N., et al. Molecular cloning of rat leptin receptor isoform complementary DNAs-identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 225 (1996) 75-83
67. Housova J., Wilczek H., Haluzik M.M., Kremen J., Krizova J., and Haluzik M. Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment. Physiol Res 54 (2005) 73-78
68. Papathanassoglou E., El-Haschimi K., Li X.C., Matarese G., Strom T., and Mantzoros C. Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol 176 (2006) 7745-7752
69. Santos-Alvarez J., Goberna R., and Sanchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 194 (1999) 6-11
70. Najib S., and Sanchez-Margalet V. Human leptin promotes survival of human circulating blood monocytes prone to apoptosis by activation of p42/44 MAPK pathway. Cell Immunol 220 (2002) 143-149
71. Hassan I.S., Bannister B.A., Akbar A., Weir W., and Bofill M. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clin Immunol Immunopathol 87 (1998) 60-67
72. Martin-Romero C., Santos-Alvarez J., Goberna R., and Sanchez-Margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 199 (2000) 15-24
73. Sanchez-Margalet V., Martin-Romero C., Santos-Alvarez J., Goberna R., Najib S., and Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 133 (2003) 11-19
74. Otero M., Lago R., Gomez R., et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 45 (2006) 944-950
75. Wenger T., and Moldrich G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 301-307
76. Roth M.D., Baldwin G.C., and Tashkin D.P. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 121 (2002) 229-239
77. Lu T., Newton C., Perkins I., Friedman H., and Klein T.W. Cannabinoid treatment suppresses the T helper cell polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther (2006)
78. Covelli V., Passeri M.E., Leogrande D., Jirillo E., and Amati L. Drug targets in stress-related disorders. Curr Med Chem 12 (2005) 1801-1809
79. Ayensu W.K., and Tchounwou P.B. Microarray analysis of mercury-induced changes in gene expression in human liver carcinoma (HepG2) Cells: importance in immune responses. Int J Environ Res Public Health 3 (2006) 141-173
80. Hilgers A., and Frank J. [Chronic fatigue syndrome: immune dysfunction, role of pathogens and toxic agents and neurological and cardial changes]. Wien Med Wochenschr 144 (1994) 399-406
81. Artsimovich N.G., Galushina T.S., Matvienko M.A., Nastoyaschaya N.N., Fadeeva T.A., and Shneidorova M.A. Immunity impairment as a result of neurohormonal disorders. Russ J Immunol 4 (1999) 343-345
82. Racciatti D., Vecchiet J., Ceccomancini A., Ricci F., and Pizzigallo E. Chronic fatigue syndrome following a toxic exposure. Sci Total Environ 270 (2001) 27-31
83. Vojdani A., and Thrasher J.D. Cellular and humoral immune abnormalities in Gulf War veterans. Environ Health Perspect 112 (2004) 840-846
84. You M., Considine R.V., Leone T.C., Kelly D.P., and Crabb D.W. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42 (2005) 568-577
85. Connor T.J. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system. Immunology 111 (2004) 357-367
86. Schnare D.W., Denk G., Shields M., and Brunton S. Evaluation of a detoxification regimen for fat stored xenobiotics. Med Hypotheses 9 (1982) 265-282
87. Shields M, Beckmann S, Tennant F, Wisner RM. Reduction of drug residues: applications in drug rehabilitation. Abstracts of the 123rd Annual Meeting of the American Public Health Association; 1995.
88. Schnare D.W., Ben M., and Shields M.G. Body burden reduction of PCBs, PBBs and chlorinated pesticides in human subjects. Ambio 13 (1984) 378-380
89. Tretjak Z., Shields M., and Beckmann S.L. PCB reduction and clinical improvement by detoxification: an unexploited approach?. Hum Exp Toxicol 9 (1990) 235-244
90. Kilburn K.H., Warsaw R.H., and Shields M.G. Neurobehavioral dysfunction in firemen exposed to polycholorinated biphenyls (PCBs): possible improvement after detoxification. Arch Environ Health 44 (1989) 345-350
91. Tsyb AF, Parshkov EM, Barnes J, Yarzutkin NV, Vorontsov NV, Dedov VI. Rehabilitation of a chernobyl affected population using a detoxification method. In: Proceedings of the 1998 International Radiological Post-Emergency Response Issues Conference; 1998. p. 160-5.
92. Barnes J.G. 'Sensitivity syndromes' related to radiation exposures. Med Hypotheses 57 (2001) 453-458